eli lilly retatrutide study Lilly's triple agonist achieves 16.8% weight loss in phase 3 trial Retatrutide clinical trial done! Now

Without making this post about life expectancy (the Washington Post had a great article about this recently ), were now dying of cancer, cardiovascular disease, hypertension, diabetes, obesity, car accidents, suicide, and opioid addiction

To understand why this class is so powerful, you have to start at the beginning with the peptides themselves

Think of peptides as communication signals

They can irritate the digestive tract and trigger indigestion

Those who have low levels of Choline have experienced liver damage known as non-alcoholic fatty liver disease, as well as muscle damage and weight gain

But for millions of people, the biggest barrier to treatment hasn't been motivation